Introduction
First discovered in Caenorhabditis elegans in 1993, microRNAs (miRNAs) are short, 19-22 bp, non-coding, single stranded RNA sequences that bind 3′-untranslated regions (UTRs) of target messenger RNAs (mRNAs) to regulate gene expression and downstream cellular functions, including immunity following virus infection (Bakre et al., 2012 (Bakre et al., , 2013 Meliopoulos et al., 2012) . miR-155, derived from the non-coding transcript of the protooncogene bic (B cell integration cluster) has been implicated in both direct and indirect regulation of B and T cell development and function (Lagos-Quintana et al., 2002; Rodriguez et al., 2007) . miR-155 is highly expressed in the thymus and bone marrow and is known to play a significant role in the regulation of CD4 + (Th1, Th2, and Th17), CD8 + , and T regulatory (Tregs) cell function (Martin et al., 2006; Seddiki et al., 2014; Spoerl et al., 2013) . Previous studies have shown that miR-155-deficient mice fail to establish protection against influenza infection due to disrupted cell-mediated and humoral immune responses (Rodriguez et al., 2007; Thai et al., 2007) . Notably, miR-155 expression in naïve T and B cells is relatively low. It is however upregulated following TCR or BCR activation suggesting it plays a critical role in inducing optimal immunity (Turner and Vigorito, 2008) .
Influenza A viruses (IAV) are members of the Orthomyxoviridae family and cause significant morbidity and mortality worldwide. Efficient IAV clearance is mediated by numerous cell types including neutrophils, NK cells, dendritic cells, B cells, CD4 + and CD8 + T cells (Schultz-Cherry, 2015; Hufford et al., 2015; Waffarn and Baumgarth, 2011) . Of particular interest is the fact that establishment of CD8+ T cell immunity has been associated with reduced viral loads. IAV infection drives recruitment, activation and differentiation of CD8 + T cell precursors (Kaech and Ahmed, 2001 ) following dendritic cell antigen processing and presentation (van Stipdonk et al., 2001) . Once activated, effector CD8 + T cells mediate viral clearance through exocytosis of cytolytic granules containing perforin and granzyme or via the interaction of FasL and Fas on target cells (Stambas et al., 2008 (Podshivalova and Salomon, 2013; Grigoryev et al., 2011) . Moreover, influenza virus infection of miR-155 knockout mice demonstrates reduced antigen specific CD8 + T cells in the lung, spleen and mediastinal lymph node during the effector phase (Gracias et al., 2013) . Transgenic mice on the other hand overexpressing miR-155 (using an integrating retroviral system not easily translatable to humans) show a substantial increase in the number of influenza-specific CD8 + T cells when compared to WT controls (Gracias et al., 2013) .
The role of miR-155 in regulating CD8 + T cell immunity is not limited to influenza A viruses. Selective depletion of miR-155 expression in CD8 + T cells using a chimeric mouse model prolonged MHV68 viral clearance and enhanced vireamia post infection in a process thought to be mediated by a reduction in functionally active IFNγ (Tsai et al., 2013) . Along with T cell effector function, miR-155 is thought to play an important role in the establishment of immunological memory.
High miR-150/miR-155 ratios have been shown to favour development of a central memory phenotype whilst low miR-150/miR-155 ratios are thought to encourage differentiation of effector cells (Almanza et al., 2010) . The exact mechanism and contribution to CD8 + T cell memory is yet to be defined. It is well-established that miR-155 also plays a key role in regulation of B cell and CD4 + T cell differentiation; cell types involved in humoral immunity (Lagos-Quintana et al., 2002; Rodriguez et al., 2007; Martin et al., 2006; Seddiki et al., 2014; Spoerl et al., 2013) . Furthermore, studies had noted that miR-155 expression is upregulated in activated germinal centres (Thai et al., 2007; Baumjohann and Ansel, 2014) and antibody class switching can be altered following miR-155 silencing of activation induced cytidine deaminase (AID) (Rodriguez et al., 2007; Vigorito et al., 2007) . The impact of miR155 on influenza-specific neutralising antibody titres following infection/vaccination is yet to be elucidated and is a key area of research given its usefulness as a correlate of protection (Chiu and Openshaw, 2015) . The relationship between miRNA expression and T and B cell responses has led to increasing interest in the development of miRNA therapeutic and vaccine adjuvant platforms. A key limitation is effective in vivo delivery of miRNAs. miRNAs need to overcome a number of obstacles to reach targets via systemic routes. For example, they must avoid degradation by nucleases, phagocytosis by immune cells, and clearance via kidney filtration (Singh et al., 2011) . Moreover, after site-specific delivery, cellular uptake of miRNAs must also occur. Viruses inherently possess the necessary attributes to circumvent these obstacles and provide a unique and novel platform for delivery (Couto and High, 2010) . A number of virus platforms have been used in the past to deliver miRNAs, including adenoviruses and lentiviruses. Issues including but not limited to integration and control of expression have all been noted as impediments for real world application (Rubinson et al., 2003; Xia et al., 2002) . In 2010, a novel influenza-based delivery system was established using reverse genetics to facilitate expression of miRNAs (Varble et al., 2010) . We utilised this system to deliver miR-155 in cell culture and noted upregulation of IFNβ and IL-6 through what we believe was targeting of the negative regulator of cytokine signalling, SOCS1 (Izzard et al., 2014) . These initial preliminary infection, **P < 0.01 compared to X31-WT infection using a Student's t-test. Three independent experiments were performed and presented as the mean ± SD of N = 5 of a representative experiment. Fig. 3 . IAV-specific neutralising antibody titres. Serum was collected from X31-155 and X31-WT mice at 10 days post infection. Neutralising antibody titres were determined using a microneutralization assay. Neutralising antibody titres were quantified as the serum dilution factor that successfully neutralised 10 4 PFU of virus. Data represents the mean ± SD of N = 5. *P < 0.05 compared to X31-WT infection using a Student's t-test.
Three independent experiments were performed with data presented as the mean ± SD of N = 5 of a representative experiment.
observations provided support for the use of genetically engineered miRNA expressing IAVs as potential self-adjuvanting vaccines. Currently, there are two types of commercially available influenza A vaccines; (i) chemically inactivated virus particles known to stimulate neutralising antibodies against circulating IAV and (ii) live -attenuated vaccines that activate both T cell and B cell immunity. Although relatively efficient, these current vaccine strategies have reduced efficacy in susceptible populations, with efficacy levels as low as 17% in the elderly, compared to as high as 90% in young adults (Goodwin et al., 2006) . This manuscript describes the use of a recombinant influenza virus expressing miR-155 for its ability to modulate adaptive immunity. We show enhanced influenza-specific CD8 + T cells numbers and neutralising antibody responses in a B6 mouse model of infection.
Materials and methods

Generation and amplification of a miR-155 expressing HKx31 (H3N2) IAV
The miR-155 expressing HKx31 (X31) IAV was rescued using a modified non-structural (NS) gene expression plasmid and reverse genetics protocols as previously described (Izzard et al., 2014) . Six internal PR8 (H1N1) gene segments (including a modified miR155 encoded NS segment) were transfected into a co-culture of 293T and MDCK cells along with HKx31 (H3N2) HA and NA gene segments to create a recombinant HKx31-155 (X31-155) virus. Virus stocks were amplified in 10-day embryonated eggs, and virus titres were determined using a plaque assay.
Infection and sample collection
Intranasal infections were performed in C57.BL/6 mice as previously described (Stambas et al., 2007) . Briefly, naive 8-wk old C57.BL/6 mice were anesthetised with isoflurane before intranasal (i.n.) infection with 10 4 plaque forming units (PFU) wild type HKx31 (H3N2) IAV (X31-WT), or a modified HKx31 (H3N2) IAV expressing miR-155 (X31-155). Mice from the X31-WT and X31-155 groups were euthanized at days 1, 3, 5, 7, and 10 pi, and lungs and spleen harvested for analyses. Single cell suspensions of spleen cells were prepared and red blood cell lysis performed using a Tris-buffered Ammonium Chloride (ATC) solution (0.14 M NH 4 Cl, 0.017 M Tris, pH 7.2) prior to tetramer analysis.
Lung virus titres
Lung viral titres was determined by plaque assay. Briefly, 6-well plates (Thermo Fisher Scientific, Australia) containing confluent MDCK cell monolayers were infected with lung homogenate for 45 mins at 37°C. Following this, 3 ml of overlay media [L15 media (Life Technologies, Australia), 0.025% NaHCO 3 , 0.4 mM HEPES, 100 U/ml Penicillin/Streptomycin (Life Technologies, Australia), 24 μg/ml Gentamycin (Life Technologies, Australia), 1 mg/ml TPCK treated trypsin (Worthington Biochemical Corporation, USA) and 0.8% agarose (Sigma-Aldrich, Australia)] was added to the wells. Plates were incubated at 37°C, 5% CO 2 for 72 h and stained with crystal violet (0.1% in 20% ethanol) to visualise and enumerate plaques. PA 224 -specific tetramers (Altman et al., 1996) for 60 min at room temperature. Enriched cells were centrifuged and resuspended in RPMI 1640 medium (Gibco, Australia) containing 100 U/ml Penicillin/Streptomycin (Life Technologies, Australia), 24 μg/ml Gentamycin (Life Technologies, Australia) and 10% FCS. Cells were subsequently washed and stained with anti-mouse CD8α-PerCP Cy5.5 (BD Biosciences, Australia) for 30 min on ice. Following staining, cells were washed twice with PBS containing 1% BSA and 0.02% NaN 2 , and analysed by flow cytometry on a BD Fortessa (BD Biosciences, Australia).
Flow cytometry analysis
Histopathology
Lung samples were fixed in a 10% Neutral Buffered Formalin (NBF) solution overnight (Australian Biostain P/L, Australia) to preserve morphology and prevent autolysis. Lungs were processed to remove water and mounted in paraffin wax before sectioned using a Leica Rotary Microtome (Leica Biosystems, Australia). Sections were stained with Haematoxylin & Eosin and anti-influenza NP antibody to detect the presence of IAV.
Microneutralization assay
Levels of neutralising antibodies were determined using a microneutralization assay adapted from a previously published method (Harmon et al., 1988) . Briefly, heat inactivated mouse serum was serially diluted in infection media [RPMI (Life Technologies, Australia) containing 100 U/ml Penicillin/Streptomycin (Life Technologies, Australia), 24 μg/ml Gentamycin (Life Technologies, Australia) and 1 mg/ ml TPCK treated trypsin (Worthington Biochemical Corporation, USA)] in a 96 well plate (Thermo Fisher Scientific, Australia). HKx31 (H3N2) IAV (500 PFU) was then added to each well and the plate incubated at 37°C, 5% CO 2 for 1 h. The cell supernantant (100 μl) was then transferred to a 96 well plate containing confluent monolayer of MDCK cells and incubated at 37°C, 5% CO 2 for 72 h. Virus was detected using a standard hemagglutination (HA) assay (Frank et al., 1980) .
Results
Weight loss and viraemia
Weight loss is an indicator of IAV pathogenesis and typically peaks at days 6-7 post-infection (pi). Intranasal infection of C57.BL/6 mice with 10 4 pfu X31-155 or X31-WT control viruses showed comparable weight loss in both groups (peaking at 7 days pi) followed by consistent weight gain until euthanasia 10 days pi (Fig. 1a) . Lung viral titres were assessed using plaque assay analysis from samples collected at days 1, 3, 7 and 10 pi. Mice infected with X31-155 or X31-WT virus exhibited comparable viral titres at all four time-points (Fig. 1b) . Histopathological analysis of lungs collected at day 3 pi showed no substantial differences between the two groups (Table 1) . (Fig. 2) . In contrast, the CD8 + D b PA 224 T-cell response remained unchanged between the two groups.
X31-155 infection results in enhanced CD8
Expression of miR-155 enhances IAV-specific humoral immunity
The majority of neutralising antibodies generated to IAV are directed against the HA and NA glycoproteins. We determined neutralising antibody titres in our experimental groups using a standard micro-neutralisation assay (Frank et al., 1980) . X31-155 infected mice produced higher neutralising antibody titres when compared to X31-WT controls (Fig. 3) .
Discussion
Previously studies from our group have shown that incorporation of miR-155 into the NS gene segment of IAV results in modulation of the antiviral response in vitro (Izzard et al., 2014) . Here, we present data that demonstrates expression of miR-155 enhances cell-mediated immunity in mice.
IAV-specific T cell responses are critical for viral clearance. The magnitude and specificity of the CD8 + T cell response is influenced by multiple host and viral determinants (Bender et al., 1992) . A highly reproducible immunological hierarchy establishes epitope-specific responses against IAV that are dependent on peptide presentation via MHC class I molecules (Yewdell and Bennink, 1999) . Naive antigenspecific CD8 + precursor T cell frequency contributes to the magnitude and hierarchy of epitope-specific responses (La Gruta et al., 2006) however precursor frequency alone does not independently determine the hierarchy of the CD8 + response (La Gruta et al., 2010) . Additional studies have determined that the magnitude and specificity of the response is also dependent on the recruitment and proliferative capacity of distinct epitope-specific precursor subpopulations (La Gruta et al., 2010) . Furthermore, magnitude can be influenced by MHC class I expression on dendritic cells, peptide stability and TCR avidity (Cukalac et al., 2014; Dinter et al., 2015) . Fig. 1 also indicated a trend for improved body weight and lower virus titres between 7 and 10 days post primary infection (although this was not statistically significant). Given the significant increases in cellular immunity normally associated with secondary infection, we would expect detectable and statistically significant changes in weight loss and lung virus tires to be observed. The direct or indirect mechanism by which miR-155 enhances D b NP 366 -specific responses is yet to be determined. We observe no substantial differences in viral titres for the X31-155 or X31 WT viruses and can therefore assume that expression of NP and PA protein is similar. C57BL/6 mice are inbred and so antigen-specific precursor frequencies should remain constant. From this we can assume that the increase observed in CD8 + D b NP 366 -specific T cell responses is unlikely to be solely attributed to changes in precursor frequency and/or antigen load. It is more likely that expression of miR-155 from our recombinant virus is altering MHC class I antigen presentation through modulation of the microenvironment in the lung or through expression in infected DCs.
Further support for this mechanism of action is derived from studies that demonstrate a decrease in MHC class II expression on dendritic cells when miR-155 is knocked down (Li et al., 2014) . Our previous studies have shown that in vitro infection of epithelial cells with PR8-155 can reduce expression of SOCS1 enhancing expression of IFN beta and IL-6 (Izzard et al., 2014) . As such in vivo infection with X31-155 may alter the cytokine microenvironment in the lung resulting in disturbances in DC activation, peptide processing, and antigen presentation. miR-155 was initially identified for its contribution to B cell immunity (Rodriguez et al., 2007) . It is upregulated in germinal centre B cells and potentially protects high affinity cells from apoptosis through inhibition of the pro-apoptotic protein, JARID2 (Nakagawa et al., 2016) . Additionally, miR-155 helps facilitate follicular T helper cell congregation in germinal centres (Hu et al., 2014) . In our studies, infection with X31-155 resulted in increased IAV-specific neutralising antibody titres. Although the mechanism for the increased antibody titres remains to be investigated, it is possible that exogenous miR-155 is indirectly contributing to enhanced expression of serum neutralising antibodies through regulation of B cell maturation or function.
Conclusions
In conclusion, we have demonstrated that inclusion of the miR-155 hairpin from the non-structural gene segment of IAV enhances D b NP 366 + CD8 + T cell responses and influenza-specific neutralising antibody activity following primary infection. These novel findings highlight the potential use of miRNAs as molecular adjuvants for IAV vaccines in a self-adjuvanting capacity.
